Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial

Stock Information for Dianthus Therapeutics Inc Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Dianthus Therapeutics Inc Com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGTA, FRG, EMAN
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGTA, CHRA, STSA
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - MGTA, STSA, ROCC, CVT
Lifshitz Law PLLC Announces Investigations of RUTH, MGTA, MDWT, and ISEE
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cvent Holding Corp. (Nasdaq - CVT), Absolute Software Corporation (Nasdaq - ABST), Home Point Capital, Inc. (Nasdaq - HMPT), Magenta Therapeutics, Inc. (Nasdaq - MGTA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGTA, RUTH, HSKA
Moore Kuehn Encourages MGTA, HSKA, RUTH and SYNH Investors to Contact Law Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.